| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature
|
Nishikawa, Go
|
|
2018
|
101 |
C |
p. 143-151
|
artikel
|
| 2 |
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients
|
Bao, Ting
|
|
2018
|
101 |
C |
p. 12-19
|
artikel
|
| 3 |
A pooled analysis of published, basket trials in cancer medicine
|
Hazim, Antonious
|
|
2018
|
101 |
C |
p. 244-250
|
artikel
|
| 4 |
A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II)
|
Nishikawa, Kazuhiro
|
|
2018
|
101 |
C |
p. 220-228
|
artikel
|
| 5 |
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma
|
Le Rhun, Emilie
|
|
2018
|
101 |
C |
p. 95-104
|
artikel
|
| 6 |
Autologous graft-versus-host disease with combined immune checkpoint blockade
|
Kofler, L.
|
|
2018
|
101 |
C |
p. 275-277
|
artikel
|
| 7 |
Breast cancer–related deaths according to grade in ductal carcinoma in situ: A Dutch population–based study on patients diagnosed between 1999 and 2012
|
van Maaren, M.C.
|
|
2018
|
101 |
C |
p. 134-142
|
artikel
|
| 8 |
Changes in treatment patterns and survival in elderly patients with stage I non–small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery
|
Detillon, Deniece D.E.M.A.
|
|
2018
|
101 |
C |
p. 30-37
|
artikel
|
| 9 |
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials
|
Sundar, Raghav
|
|
2018
|
101 |
C |
p. 55-61
|
artikel
|
| 10 |
Comment on B ratings for erythrodermic cutaneous T-cell lymphoma
|
Vonderheid, Eric
|
|
2018
|
101 |
C |
p. 281-283
|
artikel
|
| 11 |
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations
|
Kasper, Edwige
|
|
2018
|
101 |
C |
p. 254-262
|
artikel
|
| 12 |
2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
|
Kaira, Kyoichi
|
|
2018
|
101 |
C |
p. 181-190
|
artikel
|
| 13 |
Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome
|
Scarisbrick, Julia J.
|
|
2018
|
101 |
C |
p. 278-280
|
artikel
|
| 14 |
Fatal autoimmune myocarditis with anti–PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer
|
Berner, A.M.
|
|
2018
|
101 |
C |
p. 287-290
|
artikel
|
| 15 |
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
|
Aranda, E.
|
|
2018
|
101 |
C |
p. 263-272
|
artikel
|
| 16 |
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
|
Hegewisch-Becker, Susanna
|
|
2018
|
101 |
C |
p. 105-113
|
artikel
|
| 17 |
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
|
Kozuma, Yuka
|
|
2018
|
101 |
C |
p. 20-29
|
artikel
|
| 18 |
Influence of eukaryotic translation initiation factor 6 on non–small cell lung cancer development and progression
|
Gantenbein, Nadine
|
|
2018
|
101 |
C |
p. 165-180
|
artikel
|
| 19 |
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer
|
Liu, Stephen V.
|
|
2018
|
101 |
C |
p. 114-122
|
artikel
|
| 20 |
Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project
|
Thompson, Alastair M.
|
|
2018
|
101 |
C |
p. 210-219
|
artikel
|
| 21 |
Nocardiosis in a patient with anti-PD-1–associated colitis treated with infliximab
|
Glutsch, V.
|
|
2018
|
101 |
C |
p. 284-286
|
artikel
|
| 22 |
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors
|
Bouvard, B.
|
|
2018
|
101 |
C |
p. 87-94
|
artikel
|
| 23 |
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
|
Carlino, Matteo S.
|
|
2018
|
101 |
C |
p. 236-243
|
artikel
|
| 24 |
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
|
Bernard-Tessier, A.
|
|
2018
|
101 |
C |
p. 160-164
|
artikel
|
| 25 |
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
|
Rugo, Hope S.
|
|
2018
|
101 |
C |
p. 123-133
|
artikel
|
| 26 |
Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study
|
Davis, Laura E.
|
|
2018
|
101 |
C |
p. 1-11
|
artikel
|
| 27 |
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma
|
Ben-Betzalel, Guy
|
|
2018
|
101 |
C |
p. 229-235
|
artikel
|
| 28 |
Predictors of survival in neurometastatic Merkel cell carcinoma
|
Harary, Maya
|
|
2018
|
101 |
C |
p. 152-159
|
artikel
|
| 29 |
Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors
|
Mao, Huijuan
|
|
2018
|
101 |
C |
p. 47-54
|
artikel
|
| 30 |
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
|
Horn, Leora
|
|
2018
|
101 |
C |
p. 201-209
|
artikel
|
| 31 |
Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America
|
Doganis, Dimitrios
|
|
2018
|
101 |
C |
p. 38-46
|
artikel
|
| 32 |
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
|
Bonanno, L.
|
|
2018
|
101 |
C |
p. 191-200
|
artikel
|
| 33 |
The use of real-world data in cancer drug development
|
Skovlund, E.
|
|
2018
|
101 |
C |
p. 69-76
|
artikel
|
| 34 |
Tibolone is not an oestrogen but a mixture of a strong progestin and two weak oestrogens
|
Coelingh Bennink, Herjan JT.
|
|
2018
|
101 |
C |
p. 273-274
|
artikel
|
| 35 |
Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there?
|
Gronchi, Alessandro
|
|
2018
|
101 |
C |
p. 251-253
|
artikel
|
| 36 |
Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012
|
Schroten-Loef, C.
|
|
2018
|
101 |
C |
p. 77-86
|
artikel
|
| 37 |
Uterine morcellation and survival in uterine sarcomas
|
Bretthauer, Michael
|
|
2018
|
101 |
C |
p. 62-68
|
artikel
|
Tijdschrift beschrijving